FFAR1 is of particular interest because the triggering of insulin secretion is glucose-dependent, which makes it a major focus for the treatment of type 2 diabetes, as agonists will improve glycemic regulation and minimize the risk of hypoglycemia [28]. The gene discussed is INS; the disease is type 2 diabetes mellitus.